When Ketamine Doesn't Work: Setting Realistic Expectations

We believe in ketamine as a treatment. We've seen it change lives. The research supports it. The clinical outcomes for the right patients are real and substantial.

And we also believe you deserve honesty: ketamine doesn't work for everyone.

Approximately 30-40% of patients who complete a standard ketamine series don't achieve the response they hoped for. Some get partial relief. Some get none at all. This is not a moral failure, not a sign that they're untreatable, and not something a responsible provider should hide behind optimistic marketing copy.

Understanding why ketamine doesn't work — and what to do when it doesn't — is as important as understanding why it does.

The Statistics, Honestly

The published research on ketamine for treatment-resistant depression shows response rates of 60-70% — meaning that 60-70% of patients experience a clinically meaningful reduction in depression scores. That's substantially better than what SSRIs achieve in treatment-resistant patients (around 20-30%).

But it also means that roughly 30-40% of patients do not respond adequately. In pain conditions, the numbers are similar. Non-response to ketamine is common enough that it should be part of every informed consent conversation — and it isn't, at many programs.

The Most Common Reasons Ketamine Doesn't Work

**

1. Incorrect or incomplete diagnosis**

Ketamine is specifically indicated for major depressive disorder, treatment-resistant depression, PTSD, and certain pain conditions. It's not equally effective for all conditions that present with low mood or distress.

Conditions that may be misdiagnosed as depression and won't respond to ketamine include:

• Bipolar disorder (especially Bipolar II, which is chronically under-diagnosed)
• Hypothyroidism masquerading as depression
• Severe ADHD with secondary mood symptoms
• Personality disorders without significant comorbid depression
• Sleep apnea with secondary fatigue and mood changes

If your diagnosis isn't accurate, even the best treatment won't produce the expected response. See understanding treatment-resistant depression for more on this diagnostic complexity.

**

1. Inadequate dosing**

Sublingual ketamine is absorbed sublingually and has variable bioavailability — typically 25-30% of the dose reaches systemic circulation. The appropriate therapeutic dose is not a fixed number; it needs to be calibrated to body weight, individual pharmacokinetics, and clinical response.

Some patients who "don't respond" to ketamine were simply under-dosed. This is more common than most providers acknowledge, and it's one reason physician-led programs with individualized dosing protocols produce better outcomes than one-size-fits-all approaches.

**

1. Poor integration and behavioral factors**

Ketamine's benefits are not purely pharmacological. The neuroplasticity window it creates — the period of enhanced neural flexibility after each session — needs to be used. Patients who complete sessions and then return to the exact same environment, thought patterns, and behaviors that drove their depression in the first place will get less out of treatment.

Heavy alcohol use, cannabis use, or significant sleep disruption between sessions can blunt ketamine's effects. A lack of any integration practice — even simple journaling — means the neuroplasticity window closes without the new patterns being installed.

Our ketamine therapy integration guide covers what to do to maximize the integration window.

**

1. Contraindicated or complicating conditions**

Some underlying conditions significantly reduce ketamine response or create safety concerns:

• Active, uncontrolled substance use disorders
• Severe untreated sleep apnea
• Significant inflammatory conditions (ketamine may be less effective in high-inflammation states)
• Ongoing trauma exposure without safety stabilization

**

1. Insufficient number of sessions**

A single ketamine session is unlikely to produce durable antidepressant effects in most patients. The standard acute series is 4-6 sessions — and some patients need 8 or more to achieve response. Stopping after 2-3 sessions because the improvement wasn't dramatic enough is a common premature exit.

**

1. Rare pharmacogenomic factors**

A small percentage of patients metabolize ketamine very rapidly due to genetic variants in the enzymes responsible for ketamine metabolism (primarily CYP2B6 and CYP3A4). These patients may need higher doses or more frequent sessions to achieve adequate effect.

What To Do If Your Series Isn't Working

First: Communicate with your physician. Don't just quietly give up. Tell your care team exactly what you're experiencing — partial response, no response, the specific symptoms that aren't improving. This feedback enables dosing adjustments and treatment modifications.

Second: Review the diagnostic picture. If you're not responding, it's worth reconsidering whether the treatment is targeting the right condition. A thorough diagnostic re-evaluation — including thyroid function, sleep study, assessment for bipolar spectrum — is often warranted.

Third: Consider augmentation. For partial responders, combining ketamine with psychotherapy, adding an appropriate mood stabilizer, or addressing comorbid conditions (like sleep apnea) can convert a partial response into a full one.

Fourth: Think about timing and integration. Have you been drinking between sessions? Using cannabis daily? Not sleeping? These factors matter more than most patients realize.

Fifth: Consider escalation or alternative approaches. If ketamine genuinely doesn't work after an adequate trial (appropriate dosing, 6+ sessions, good integration), the honest next conversation is about alternatives: TMS (transcranial magnetic stimulation), ECT (electroconvulsive therapy, which has the highest response rate of any treatment for refractory depression), MAOI antidepressants, or specialized psychiatric care.

What This Means for Your Expectations Going In

We want every patient to approach ketamine with realistic expectations:

• Most patients (60-70%) achieve meaningful improvement
• Some patients (20-30%) get partial improvement that is worth building on
• A minority (10-20%) don't achieve meaningful benefit from an adequate trial
• Results vary by condition, dose, integration, and individual biology

This is better than what SSRIs offer. It's real, meaningful treatment that changes lives for a majority of the patients who try it. But it's not a guarantee — and pretending it is would be both dishonest and ultimately harmful.

If you're wondering whether your specific history and symptoms make you a good candidate, take our eligibility quiz. Our physicians look at each case individually and will give you an honest assessment of what ketamine might realistically do for you. You can also explore our full treatment resources to learn more about what to expect.

You deserve honesty. That's what we'll give you.